Accès gratuit
Colon Rectum
Volume 10, Numéro 1, Février 2016
Recommandations pour la pratique clinique - Cancer du rectum
Page(s) 55 - 61
Section Dossier Thématique / Thematic File
Publié en ligne 15 décembre 2015
  • Andre T, Boni C, Navarro M, et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 :3109–16 [CrossRef] [PubMed]
  • Haller DG, Tabernero J, Maroun J, et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29 :1465–71 [CrossRef] [PubMed]
  • Yothers G, O'Connell MJ, Allegra CJ, et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29 :3768–74 [CrossRef] [PubMed]
  • Sauer R, Becker H, Hohenberger W, et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 :1731–40 [CrossRef] [PubMed]
  • Valentini V, van Stiphout RG, Lammering G, et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29 :3163–72 [CrossRef] [PubMed]
  • Artru P. (2007) Recommendations for clinical practice. Therapeutic choices for rectal cancer. What role should adjuvant treatment play after oncological surgery for rectal cancer? Gastroenterol Clin Biol 31 Spec No 1: 1S81–88, S102-3 [CrossRef] [PubMed]
  • Maas M, Nelemans PJ, Valentini V, et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11 :835–44 [CrossRef] [PubMed]
  • Nagtegaal ID, van de Velde CJ, van der Worp E, et al (2002) Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 20 :1729–34 [CrossRef] [PubMed]
  • Rodel C, Martus P, Papadoupolos T, et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23 :8688–96 [CrossRef] [PubMed]
  • Dworak O, Keilholz L, Hoffmann A. (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 :19–23 [CrossRef] [PubMed]
  • Ruo L, Tickoo S, Klimstra DS, et al (2002) Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236 :75–81 [CrossRef] [PubMed]
  • Arredondo J, Baixauli J, Beorlegui C, et al (2013) Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. Dis Colon Rectum 56 :416–21 [CrossRef] [PubMed]
  • Liersch T, Langer C, Ghadimi BM, et al (2006) Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 24 :4062–8 [CrossRef] [PubMed]
  • Kuo LJ, Liu MC, Jian JJ, et al (2007) Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 14 :2766–72 [CrossRef] [PubMed]
  • Hohenberger W, Bittorf B, Papadopoulos T, Merkel S. (2005) Survival after surgical treatment of cancer of the rectum. Langenbecks Arch Surg 390: 363–372. [CrossRef] [PubMed]
  • Chand M, Bhangu A, Wotherspoon A, et al (2014) EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Ann Oncol 25 :858–63 [CrossRef] [PubMed]
  • Chand M, Evans J, Swift RI, et al (2015) The prognostic significance of postchemoradiotherapy high-resolution MRI and histopathology detected extramural venous invasion in rectal cancer. Ann Surg 261 :473–9 [CrossRef] [PubMed]
  • Hogan J, Chang KH, Duff G, et al (2015) Lymphovascular invasion: a comprehensive appraisal in colon and rectal adenocarcinoma. Dis Colon Rectum 58 :547–55 [CrossRef] [PubMed]
  • Lee JH, Jang HS, Kim JG, et al (2012) Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision. Ann Surg Oncol 19 :1213–21 [CrossRef] [PubMed]
  • Cienfuegos JA, Rotellar F, Baixauli J, et al (2015) Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol 22 :916–23 [CrossRef] [PubMed]
  • Reyngold M, Niland J, ter Veer A, et al (2014) Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. J Natl Compr Canc Netw 12 :235–43 [CrossRef] [PubMed]
  • Gunderson LL, Sargent DJ, Tepper JE, et al (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22 :1785–96 [CrossRef] [PubMed]
  • Sakamoto J, Ohashi Y, Hamada C, et al (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22 :484–92 [CrossRef] [PubMed]
  • Sakamoto J, Hamada C, Yoshida S, et al (2007) An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 96 :1170–7 [CrossRef] [PubMed]
  • Petersen SH, Harling H, Kirkeby LT, et al (2012) Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 3: CD004078
  • 2000) Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 355 :1588–96 [CrossRef] [PubMed]
  • Quasar Collaborative G, Gray R, Barnwell J, et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 :2020–9 [CrossRef] [PubMed]
  • Bosset JF, Collette L, Calais G, et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355 :1114–23 [CrossRef] [PubMed]
  • Sainato A, Cernusco Luna Nunzia V, Valentini V, et al (2014) No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113 :223–9 [CrossRef] [PubMed]
  • Breugom AJ, van Gijn W, Muller EW, et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trialdagger. Ann Oncol 26 :696–701 [CrossRef] [PubMed]
  • Collette L, Bosset JF, den Dulk M, et al (2007) Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25 :4379–86 [CrossRef] [PubMed]
  • Bosset JF, Calais G, Mineur L, et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15 :184–90 [CrossRef] [PubMed]
  • Breugom AJ, Swets M, Bosset JF, et al (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16 :200–7 [CrossRef] [PubMed]
  • Hong YS, Nam BH, Kim KP, et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15 :1245–53 [CrossRef] [PubMed]
  • Glynne-Jones R, Counsell N, Quirke P, et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25 :1356–62 [CrossRef] [PubMed]
  • Rodel C, Liersch T, Fietkau R, et al (2014 (suppl; abstr 3500)) Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 32 [CrossRef] [PubMed]
  • Schmoll HJ, Haustermans K, Price TJ, et al (2014 (suppl; abstr 3501)) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. J Clin Oncol 32.
  • Rodel C, Liersch T, Becker H, et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13 :679–87 [CrossRef] [PubMed]
  • Nagtegaal ID, Quirke P. (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26 :303–12 [CrossRef] [PubMed]
  • Tilly C, Lefevre JH, Svrcek M, et al (2014) R1 rectal resection: look up and don't look down. Ann Surg 260: 794–9; discussion 799-800 [CrossRef] [PubMed]
  • Debove C, Maggiori L, Chau A, et al (2015) What happens after R1 resection in patients undergoing laparoscopic total mesorectal excision for rectal cancer? A study in 333 consecutive patients. Colorectal Dis 17 :197–204 [CrossRef] [PubMed]
  • Sauer R, Liersch T, Merkel S, et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30 :1926–33 [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.